New flu vaccine for seniors passes first safety check
NCT ID NCT07421050
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing whether a new flu vaccine with an adjuvant (a booster ingredient) is safe for adults aged 65 and older. Eighty volunteers will receive a single shot and be monitored for side effects over a year. The study does not yet test if the vaccine prevents flu, only its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Subunit Influenza Vaccine (Adjuvant)
- What this could lead to
- If this vaccine is found safe, it could lead to a better flu shot for older adults, who are at higher risk of severe flu.
- What could go wrong
- This is a very early Phase 1 trial with only 80 people, so it can't prove the vaccine works. It only checks for immediate safety issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gucheng County Center for Disease Control and Prevention
Xiangyang, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Flu vaccine showdown: which shot protects seniors best?
- Can a simple breath test catch flu in High-HIV regions?
- Can a simple mask stop the flu? 2,000 volunteers put it to the test
- Can a stronger flu shot better protect seniors?
- Flu shot showdown: Cell-Grown vs recombinant vaccine put to the test
- Large-Scale flu vaccine safety study targets rare side effects